Back

MS Bio targets U.S. market with suture-free amniotic lens

Verifying
  • MS Bio plans U.S. expansion with its suture-free AM Lens product.
  • MS Bio is offering 4 million IPO shares at 6,800 won to 7,800 won.
  • The company aims to acquire a U.S. tissue bank and list on KOSDAQ this month.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.